Avidity Biosciences Stock Performance
| RNA Stock | USD 29.66 0.50 1.71% |
The firm shows a Beta (market volatility) of 1.11, which signifies a somewhat significant risk relative to the market. Avidity Biosciences returns are very sensitive to returns on the market. As the market goes up or down, Avidity Biosciences is expected to follow. At this point, Avidity Biosciences has a negative expected return of -0.62%. Please make sure to confirm Avidity Biosciences' accumulation distribution, and the relationship between the value at risk and day typical price , to decide if Avidity Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Avidity Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return (4.49) | Five Day Return (10.88) | Year To Date Return (6.48) | Ten Year Return 2.32 | All Time Return 2.32 |
1 | A New Dogma Of Molecular Biology A Paradigm Shift | 12/03/2024 |
2 | Disposition of 24000 shares by W Flanagan of Avidity Biosciences at 35.7667 subject to Rule 16b-3 | 12/11/2024 |
3 | Disposition of 25000 shares by Teresa McCarthy of Avidity Biosciences at 14.22 subject to Rule 16b-3 | 12/16/2024 |
4 | Insider Trading | 01/06/2025 |
5 | Disposition of 2032 shares by Hughes Steven George of Avidity Biosciences at 28.5906 subject to Rule 16b-3 | 01/21/2025 |
6 | Disposition of 5629 shares by Kathleen Gallagher of Avidity Biosciences at 30.1609 subject to Rule 16b-3 | 01/22/2025 |
7 | Disposition of 1221 shares by Teresa McCarthy of Avidity Biosciences at 28.5968 subject to Rule 16b-3 | 01/23/2025 |
8 | Avidity Biosciences Trading Up 6 percent Time to Buy | 01/27/2025 |
9 | miRecule and GBI Biomanufacturing Announce Strategic Partnership to Advance Development of Antibody RNA Conjugate Therapies | 01/28/2025 |
10 | MicroRNA Market Outlook Report 2025-2030 MicroRNA Services Segment Leads Growth as Outsourcing Gains Traction | 01/29/2025 |
11 | Mirvie RNA Platform First to Uncover Unique Molecular Signal for Babies at Risk of Severe Fetal Growth Restriction | 01/30/2025 |
12 | Disposition of 5875 shares by Kathleen Gallagher of Avidity Biosciences at 16.65 subject to Rule 16b-3 | 02/03/2025 |
13 | Aro Biotherapeutics Announces U.S. FDA Clearance of IND Application for ABX1100 for Potential Treatment of Late-Onset Pompe Disease | 02/05/2025 |
14 | Molecular Instruments RNA In Situ Hybridization Technology Enables Breakthrough Laboratory-Developed Tests to Advance Precision Medicine for Inflammatory Skin D... | 02/11/2025 |
15 | Janus Henderson Group PLC Expands Holdings in Avidity Biosciences Inc | 02/14/2025 |
16 | EnPlusOne Biosciences Raises 10M in Financing | 02/19/2025 |
17 | Avidity Biosciences Inc Announces Participation in Upcoming Investor Conferences | 02/25/2025 |
| Begin Period Cash Flow | 340.6 M |
Avidity |
Avidity Biosciences Relative Risk vs. Return Landscape
If you would invest 4,303 in Avidity Biosciences on November 28, 2024 and sell it today you would lose (1,387) from holding Avidity Biosciences or give up 32.23% of portfolio value over 90 days. Avidity Biosciences is generating negative expected returns assuming volatility of 3.1938% on return distribution over 90 days investment horizon. In other words, 28% of stocks are less volatile than Avidity, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Avidity Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Avidity Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Avidity Biosciences, and traders can use it to determine the average amount a Avidity Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1937
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RNA |
Estimated Market Risk
| 3.19 actual daily | 28 72% of assets are more volatile |
Expected Return
| -0.62 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.19 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Avidity Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Avidity Biosciences by adding Avidity Biosciences to a well-diversified portfolio.
Avidity Biosciences Fundamentals Growth
Avidity Stock prices reflect investors' perceptions of the future prospects and financial health of Avidity Biosciences, and Avidity Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Avidity Stock performance.
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.18 | ||||
| Operating Margin | (42.01) % | ||||
| Current Valuation | 1.9 B | ||||
| Shares Outstanding | 119.31 M | ||||
| Price To Earning | (12.91) X | ||||
| Price To Book | 2.31 X | ||||
| Price To Sales | 343.88 X | ||||
| Revenue | 9.56 M | ||||
| Gross Profit | (250.67 M) | ||||
| EBITDA | (233.5 M) | ||||
| Net Income | (212.22 M) | ||||
| Cash And Equivalents | 398.22 M | ||||
| Cash Per Share | 7.64 X | ||||
| Total Debt | 9.85 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 12.00 X | ||||
| Book Value Per Share | 12.64 X | ||||
| Cash Flow From Operations | (119.06 M) | ||||
| Earnings Per Share | (2.88) X | ||||
| Market Capitalization | 3.48 B | ||||
| Total Asset | 628.55 M | ||||
| Retained Earnings | (570.76 M) | ||||
| Working Capital | 530.63 M | ||||
| Current Asset | 50.65 M | ||||
| Current Liabilities | 16.97 M | ||||
About Avidity Biosciences Performance
By analyzing Avidity Biosciences' fundamental ratios, stakeholders can gain valuable insights into Avidity Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Avidity Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Avidity Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.30) | (0.32) | |
| Return On Capital Employed | (0.49) | (0.47) | |
| Return On Assets | (0.30) | (0.32) | |
| Return On Equity | (0.49) | (0.46) |
Things to note about Avidity Biosciences performance evaluation
Checking the ongoing alerts about Avidity Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Avidity Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Avidity Biosciences generated a negative expected return over the last 90 days | |
| Avidity Biosciences has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 9.56 M. Reported Net Loss for the year was (212.22 M) with loss before taxes, overhead, and interest of (250.67 M). | |
| Avidity Biosciences has about 398.22 M in cash with (119.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.64. | |
| Over 95.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Avidity Biosciences Inc Announces Participation in Upcoming Investor Conferences |
- Analyzing Avidity Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Avidity Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Avidity Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Avidity Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Avidity Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Avidity Biosciences' stock. These opinions can provide insight into Avidity Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Avidity Stock analysis
When running Avidity Biosciences' price analysis, check to measure Avidity Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avidity Biosciences is operating at the current time. Most of Avidity Biosciences' value examination focuses on studying past and present price action to predict the probability of Avidity Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avidity Biosciences' price. Additionally, you may evaluate how the addition of Avidity Biosciences to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |